Ask about this productRelated genes to: PRKRA Blocking Peptide
- Gene:
- PRKRA NIH gene
- Name:
- protein activator of interferon induced protein kinase EIF2AK2
- Previous symbol:
- -
- Synonyms:
- PACT, RAX, HSD14, DYT16
- Chromosome:
- 2q31.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-12-07
- Date modifiied:
- 2016-01-06
Related products to: PRKRA Blocking Peptide
Related articles to: PRKRA Blocking Peptide
- Childhood-onset dystonia (COD) encompasses a clinically and etiologically heterogeneous group of disorders, often with overlapping features. Genetic testing plays a pivotal role in uncovering underlying causes, identifying treatable subtypes, and informing individualized management strategies. - Source: PubMed
Publication date: 2026/06/16
Yilmaz SanemSerdaroglu EsraSimsek ErdemKara BulentTurkdogan DilsadYis UlucErol IlknurYuksel DenizKanmaz SedaEroglu ArzuCanpolat MehmetKomur MustafaCıtak Kurt NeseSakarya Gunes AyferSoydemir DidemBesen SeydaBektas OmerKirik SerkanAtalay Celik HaleArdicli DidemAksoy AyseYarar CoskunCerci Kubur CisilOlgac Dundar NihalGungor OlcayKamasak TulayOlculu Cemile BusraGumus HakanYildirim MiracIsik EsraAtik TahirCogulu OzgurBasak Ayse NazliSunnetci Akkoyunlu DenizÖzbakır Derya HazalKayhan GülsümGerik Çelebi Hamide BetulKaraer KadriDundar MunisKaiyrzhanov RauanCeylaner SerdarPer HuseyinHiz Ayse SemraCansu AliOkuyaz CetinAnlar BanuTekgul Hasan - PACT (PKR activating protein)/PRKRA is a quintessential double-stranded RNA (dsRNA) binding protein that has recently surfaced as a novel and compelling antiviral target, exhibiting resistance against a spectrum of respiratory viruses. Despite this, no antiviral ligand compounds targeting PACT have been identified to date. In this study, we conducted an extensive screening within natural products, leading to the development of an exceptional PACT-T78 site ligand, tubeimoside II (TBM II). TBM II effectively combats a spectrum of respiratory viruses, including the coronaviruses HCoV-OC43 and SARS-CoV-2, as well as the influenza A H1N1 virus (IAV-H1N1), by reducing viral loads and inhibiting viral replication and proliferation both and . Single-cell RNA sequencing demonstrated that TBM II significantly impacts the RIG-I signaling pathway associated with PACT. We found that when PACT was knocked down or when RIG-I, MAVS, or IFN- were knocked out, the ability of TBM II to activate the RIG-I signaling pathway was diminished, resulting in a corresponding attenuation of its antiviral efficacy. These findings indicated that TBM II targets PACT to activate the RIG-I signaling pathway, thereby increasing the secretion of type I interferon IFN-, ultimately promoting the innate immune response and achieving antiviral efficacy. In summary, our work identified TBM II as a new generation PACT ligand that activating the RIG-I signaling pathway, achieving broad-spectrum antiviral effects. - Source: PubMed
Publication date: 2026/03/14
Liu XianXie DanCui MengyaoLi ShuranYang XiaoweiZhang JuanZhang YuCao ShanBao LeiGeng ZihanSun JingZhao RonghuaGao ShuangrongCui XiaolanSun ChengpengGuo Shanshan - Idiopathic venous thromboembolism (VTE) occurs in the absence of provoking factors, limiting the efficacy of current risk stratification. In parallel, the lack of integration between transcriptomic data and established risk factors prevents the identification of individuals with a high baseline predisposition. - Source: PubMed
Publication date: 2026/05/20
Ezquerra-Condeminas PolMartinez-Perez AngelHowald CedricBrown Andrew ASouto Juan CarlosViñuela AnaBuil AlfonsoPerera-Lluna AlexandreSoria Jose Manuel - - Source: PubMed
Publication date: 2026/03/24
Bradley MaeveMaher SenanEspinoza-Vinces ChristianGorman KathleenLynch TimWalsh Richard AEspay Alberto JFearon Conor - - Source: PubMed
Publication date: 2026/03/11
Roshwanth ASingh RamandeepVellingiri BalachandarGaddigoudar MadhuWander Arvinder